Founder, President, CEO
Michael Heffernan is the Founder, President and CEO of Collegium Pharmaceutical, Inc. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. He was previously the Founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix. Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of healthcare companies. His past board memberships include; TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), Ocata (sold to Astellas), and PreCision Dermatology. Michael is currently the Chairman of the board for Veloxis Pharmaceuticals (OMX:VELO) and serves on the board for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Executive Vice President and Chief Financial Officer
Paul Brannelly joined Collegium Pharmaceutical in February 2015 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Paul held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded, clinical-stage pharmaceutical company. Prior to Karyopharm, Paul served as Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly traded biotechnology company. Earlier in his career, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With 18 years in the biopharmaceutical industry, Paul has raised $1.0 billion in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.
Executive Vice President and Chief Operating Officer
Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining the Collegium, Mr. Ciaffoni, served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Mr. Ciaffoni held various positions of increasing responsibility at Biogen Idec, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen Idec, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Mr. Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.
ALISON B. FLEMING, Ph.D.
Chief Technology Officer
Dr. Alison Fleming joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Dr. Fleming is an inventor on several United States Patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.
DOUGLAS R. CARLSON
Vice President, Corporate Development & Strategic Commercial Channels
Doug Carlson joined Collegium Pharmaceutical in 2013 and currently serves as Vice President, Corporate Development & Strategic Commercial Channels. In this capacity, Doug is responsible for Business and Corporate Development in addition to the Hospital and Long-term Care businesses. Doug has a multi-disciplinary background in M&A, venture capital, corporate finance and business development with both large and emerging growth healthcare companies. Prior to joining Collegium, Doug was Senior Director of Business Development at BTG International Inc. where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG, Doug was Senior Director and Head of Business Development for Lundbeck Inc., the U.S. Headquarters of H. Lundbeck A/S. Prior to Lundbeck, Doug was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of Ovation to Lundbeck in 2009. Prior to Ovation, Doug was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Doug started his career in the healthcare investing banking group SG Cowen & Co. He received a Bachelor of Arts degree in American Studies from Trinity College in Hartford, Connecticut.
MICHAEL DEGEORGE, PharmD
Vice President, Medical Affairs
Dr. Michael DeGeorge serves as Vice President of Medical Affairs for Collegium Pharmaceutical. Prior to joining Collegium in August of 2015, Dr. DeGeorge was the Director of Medical Affairs for Ameritox, where he a led a team of field-based scientists and oversaw the research and publication strategy. Prior to Ameritox he held Medical Affairs positions in the pharmaceutical industry, including positions at King Pharmaceuticals, Archimedes, and sanofi-aventis. Dr. DeGeorge has supported multiple pain medications, including multiple abuse-deterrent opioid formulations, and has presented original research at many scientific congresses. He earned a Bachelor’s degree in Pharmacy from St. John’s University in New York and a Doctor of Pharmacy Degree from the University of Florida.
Vice President, Marketing
Raimonds Dzelme joined Collegium Pharmaceutical in November 2016 as Vice President of Marketing. Raimonds has 20 years of experience in the healthcare industry, including pharmaceutical manufacturers, advertising, market research, and consulting companies. Raimonds was Senior Director of Neurology Marketing at Lundbeck, Inc., the US headquarters of H. Lundbeck A/S, where he led two brands. Prior to Lundbeck Raimonds served as Senior Vice President of Account Services at Palio (an inVentiv Health company), Vice President of Account Services at Saatchi & Saatchi Healthcare, Director of Strategic Consulting Services at TargetRx, Associate at Eli Lilly & Company, and Manager at Coopers & Lybrand (PwC). Raimonds received his Bachelor of Science in Business from the University of the Pacific, and his MBA from Thunderbird School of Global Management.
Vice President, Sales
Jack Maroney joined Collegium Pharmaceutical in October 2015 as Vice President of Sales. Jack has more than 25 years of diverse pharmaceutical manufacturer experience in sales, national accounts, business analytics, marketing, managed markets, sales leadership, and building high performing sales teams. Prior to joining Collegium, Jack was Vice President of Specialty Markets Sales at Sunovion Pharmaceuticals, where he led a 200-person specialty sales team. At Sunovion, Jack served as Regional Business Manager, Marketing Director, National Account Director, Area Sales Director, and Regional Sales Director. Prior to Sunovion, Jack worked at Roche Laboratories where he held a variety of field sales roles such as Regional Account Director, Division Sales Manager, Business Unit Manager, Medical Center Representative, and Sales Representative. Jack received his Bachelor of Arts degree in Business and Economics from St. Anselm College and his MBA from Babson College.
Vice President, Market Access and Trade
Kevin O’Keeffe joined Collegium in July 2015 as Vice President of Market Access and Trade. Kevin has more than 15 years of experience spanning industry and consulting. Most recently, Kevin was Senior Director of Strategic Pricing, Access & Reimbursement at Cubist Pharmaceuticals where he was responsible for leading the pricing, managed care contracting, patient access, and payer marketing functions across Cubist’s portfolio of acute care medicines. Prior to joining Cubist, Kevin was a Principal with the life sciences consulting practice at Charles River Associates where he advised pharmaceutical clients on pricing strategy, managed care contracting, and payer marketing across a range of therapeutic areas. Prior to Charles River Associates, Kevin was a Principal with Hoffman Alvary & Company where he advised clients in connection with patent licensing transactions and patent licensing disputes. Kevin received his B.A. from Bowdoin College and his M.B.A. from Georgetown University.
STEVEN D. PASSIK, Ph.D.
Vice President, Scientific Affairs, Education and Policy
After a 25 year academic and clinical career at Memorial Sloan Kettering Cancer Center, University of Kentucky and Vanderbilt University, Dr. Passik spent the past 4 years in the toxicology and most recently the pharmaceutical industry. His research has focused on psychiatric aspects of cancer and non-cancer pain and symptom management and the interface of pain management and addiction. He has served as editor and reviewer for multiple journals in pain and psycho-oncology. He has authored over 200 scholarly publications.
SAID SAIM, Ph.D.
Vice President, Pharmaceutical Development
Said Saim holds a Ph.D. and a M.S. in Chemical Engineering from the University of Kansas. He was Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research in Lawrence, Kansas prior to joining Boehringer Ingelheim Pharmaceuticals, Inc. in 1996. At BIPI, Said was a Senior Principal Scientist and led a team of Engineers and Scientists in charge of process development, scale up and technology transfer of North American products. He joined Collegium Pharmaceutical in 2008 as a Senior Director of Pharmaceutical Development. Said has published 22 papers in Engineering and Science Journals and holds 18 patents.
Vice President, Commercial Operations
Mary Theriault serves as Vice President of Commercial Operations for Collegium Pharmaceutical. Prior to joining Collegium in November 2014, Mary was the Director of Marketing at PreCision Dermatology and was instrumental in the formative years in developing, building and maintaining the infrastructure, systems and processes required for product launch and commercialization. In addition, Mary led the development and management of patient-access initiatives and marketing operations. Prior to PreCision, Mary was the Marketing Director at Innovative Clinical Solutions (pharmaceutical contract research organization) where she managed corporate and patient marketing functions. Mary held prior positions in product management, product development and account management. Mary earned her Bachelor of Science degree in Marketing from Quinnipiac University.
JOHN WEET, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
Dr. John (Jack) Weet joined Collegium Pharmaceutical in June 2015 as Vice President, Regulatory Affairs and Quality Assurance. Prior to joining Collegium, Dr. Weet was Vice President of Regulatory Affairs at Durata Therapeutics, Vertex Pharmaceuticals, and Bausch and Lomb, where he was closely involved with the submissions of Dalvance® (dalbavancin), Incivek® (telaprevir), and Besivance® (besifloxicin), respectively. In addition, Dr. Weet was on the faculty of the Pharmaceutical Education and Research Institute (PERI), a guest lecturer at Georgia Institute of Technology, a member of the Long Island University Curriculum Planning Committee of the Arnold and Marie Schwartz College of Pharmacy, and has authored various papers and presentations at industry conferences. Dr. Weet is a graduate of St. Lawrence University and holds his Ph.D. in Medical Physiology from the Ohio State University.